PR92376

SALT LAKE CITY, Oct. 19, 2021 /PRNewswire=KYODO JBN/--

--Chairman and CEO Flagg Flanagan Among 100 Most Intriguing Entrepreneurs at

2021 Builders + Innovators Summit

DiscGenics (https://c212.net/c/link/?t=0&l=en&o=3325236-1&h=3446871833&u=https%3A%2F%2Fwww.discgenics.com%2F&a=DiscGenics), Inc.,

a clinical stage biopharmaceutical company focused on developing

regenerative cell-based therapies that alleviate pain and restore function in

patients with degenerative diseases of the spine, today announced that Goldman

Sachs (https://c212.net/c/link/?t=0&l=en&o=3325236-1&h=380402140&u=https%3A%2F%2Fwww.goldmansachs.com%2Findex.html&a=Goldman+Sachs) (NYSE:GS) recognized DiscGenics Chairman and CEO Flagg Flanagan as one of the

100 Most Intriguing Entrepreneurs of 2021 at its Builders + Innovators Summit

in Healdsburg, California.

Photo - https://mma.prnewswire.com/media/1661795/FlaggFlanagan.jpg

Logo - https://mma.prnewswire.com/media/561675/DiscGenics_Logo.jpg

Goldman Sachs selected Mr. Flanagan as one of 100 entrepreneurs from multiple

industries to be honored at the two-day event.

Mr. Flanagan has over 30 years of experience in the medical device field as an

entrepreneur, executive and advisor. He has led DiscGenics since its founding

in 2007 and has overseen its evolution from pre-clinical to clinical phase with

its first product candidate, IDCT (rebonuputemcel), an injectable disc cell

therapy, now in clinical trials in the U.S. and Japan for degenerative disc

disease (DDD).

"I am honored to receive this recognition from Goldman Sachs and to be among

such an innovative group of entrepreneurs," said Mr. Flanagan. "I am extremely

proud of our team at DiscGenics and remain incredibly excited about the

opportunity before us to potentially help millions of patients with

debilitating back pain."

Prior to DiscGenics, Mr. Flanagan founded Flanagan Instruments, which he built

over 24 years into a leading neurosurgical device distribution business before

selling it to Itochu International in 2005. Mr. Flanagan is currently on the

boards of TrueDigital Systems, Peleton Medical, Triad Life Sciences, Steribite,

and the Neurosurgery Research & Education Foundation. He has also served on the

boards of the Alliance for Regenerative Medicine, as well as TrueVision Systems

and Image Stream Medical, which were acquired by Alcon and Olympus,

respectively.

"Innovation doesn't happen just anywhere; it thrives where there's a wide range

of thoughts and perspectives," said David M. Solomon, Chairman & CEO of Goldman

Sachs. "One of our great strengths is our ability to bring together people from

different walks of life and to spark conversations today that will lead to

breakthroughs tomorrow. The leaders we've chosen to highlight at our Builders +

Innovators Summit are truly remarkable, and we are pleased to recognize Flagg

Flanagan as one of this year's most intriguing entrepreneurs."

In addition to honoring 100 entrepreneurs, the summit consists of general

sessions and clinics led by seasoned entrepreneurs, academics and business

leaders as well as resident scholars.

About DiscGenics

DiscGenics is a privately held, clinical stage biopharmaceutical company

focused on developing regenerative cell-based therapies that alleviate pain and

restore function in patients with degenerative diseases of the spine. As the

only company in the world to develop an allogeneic cell therapy derived from

intervertebral disc cells to treat diseases of the disc, DiscGenics believes it

has a unique opportunity to harness the restorative potential of the human body

to heal millions of patients suffering from the debilitating effects of back

pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic,

injectable cell therapy that utilizes biomedically engineered progenitor cells

derived from intervertebral disc tissue, known as Discogenic Cells, to offer a

non-surgical, potentially regenerative solution for the treatment of patients

with mild to moderate degenerative disc disease. For more information, visit:

https://discgenics.com.

SOURCE:  DiscGenics, Inc.

Media Contacts: Lindsey Saxon

                lindsey@discgenics.com;

                Colin Novick (Japan)

                colin.lee.novick@cj-partners.com